124184-67-4

Basic information

• Product Name: D-Aspartic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 4-methyl ester
• Synonyms: D-Aspartic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 4-methyl ester;Boc-D-aspartic acid-beta-Methyl ester;(R)-2-((tert-Butoxycarbonyl)aMino)-4-Methoxy-4-oxobutanoic acid;(Tert-Butoxy)Carbonyl D-Asp(OMe)-OH
• CAS NO: 124184-67-4
• Molecular Formula: C₁₀H₁₇NO₆
• Molecular Weight: 247.24508
• Mol File: 124184-67-4.mol

Chemical Properties

• Boiling Point: 411.5±40.0 °C(Predicted)
• Appearance: /
• Density: 1.209±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.65±0.23(Predicted)
• CAS DataBase Reference: D-Aspartic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 4-methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: D-Aspartic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 4-methyl ester(124184-67-4)
• EPA Substance Registry System: D-Aspartic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 4-methyl ester(124184-67-4)

Safety Data

• Hazardous Substances Data: 124184-67-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
D-Aspartic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 4-methyl ester is used as a drug candidate for its potential therapeutic implications in neuroscience, endocrinology, and oncology. Its unique structure and properties make it a promising candidate for the development of novel treatments in these fields.
Used in Chemical Research:
D-Aspartic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 4-methyl ester is used as a building block in organic synthesis, allowing researchers to create new compounds with potential applications in various industries. Its versatility as a chemical intermediate makes it valuable for the preparation of a wide range of compounds.
Used in Biochemistry and Biotechnology:
D-Aspartic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 4-methyl ester is utilized in biochemistry and biotechnology for further studies and applications. Its unique properties and characteristics contribute to the understanding of biological processes and the development of innovative solutions in these fields.

Upstream product

• 67-56-1 methanol 
• 7536-58-5 BOC-L-aspartic acid 4-benzyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 16856-13-6 (+)-β-methyl-L-aspartate hydrochloride 
• 158201-15-1 α-benzyl β-methyl N^α-tert-butoxycarbonyl-(S)-aspartate 
• 2177-62-0 β-methyl L-aspartate 
• 1054666-03-3 (3S,4S)-3-tert-Butoxycarbonylamino-4,5-dihydroxy-pentanoic acid methyl ester 
• 784191-90-8 methyl (3S)-3-[(tert-butoxycarbonyl)amino]-3-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]propanoate 
• 23513-84-0 Boc-D-Asp(OBzl)-OH*DCHA 
• 34619-03-9 tert-butyldicarbonate 
• 21394-81-0 (R)-2-amino-4-methoxy-4-oxobutanoic acid 
• 1783-96-6 (2R)-aspartic acid 
• 22728-89-8 D-2-amino-3-methoxycarbonylpropionic acid hydrochloride 
• 6384-18-5 dimethyl D-aspartate 

Downstream Products

• 1026489-04-2 (S)-N-Benzyl-3-tert-butoxycarbonylamino-N-butyl-succinamic acid methyl ester 
• 1026567-87-2 (S)-3-tert-Butoxycarbonylamino-N-phenethyl-succinamic acid methyl ester 
• 136703-59-8 (3S)-3-[(tert-butoxycarbonyl)amino]-4-hydroxybutanoic acid methyl ester 

Relevant articles and documents

Stereoselective Synthesis of Protected l - Allo -Enduracididine and l -Enduracididine via Asymmetric Nitroaldol Reaction

The diastereoselecetive and scalable synthesis of cyclic guanidine-containing nonproteinoginic amino acids, enduracididines, has been achieved. Both diastereomers, l - allo -enduracididine and l -enduracididine, were prepared via catalyst-controlled asymmetric nitroaldol reaction with the aldehyde precursor derived from l -aspartic acid. The cyclic guanidine of di-Cbz-protected l - allo -enduracididine was fully protected with an allyl group to suppress nucleophilic side reactions. Introduced allyl group was efficiently removed via π-allylpalladium chemistry without attaching the Cbz group on the cyclic guanidine moiety.

Synthesis of desmosine-d4: Improvement of isotopic purity by D-H exchange of amino groups

Desmosine is a crosslinking pyridinium amino acid of elastin, which is a useful biomarker for the diagnosis of chronic obstructive pulmonary disease (COPD) by LC–MS/MS analysis. We previously reported a synthesis of desmosine-d4, which is useful as an internal standard for quantitative LC–MS/MS analysis of desmosines, by deuterogenation of an alkyne group; however, the isotopic purity of the desmosine-d4was only ca. 50%. The present report describes a new synthesis of desmosine-d4that improves the isotopic purity to ca. 90% by exchanging the protons of the amino groups to deuterium using deuterogenation.

Facile synthesis of urea-and thiocarbamate-tethered glycosyl beta-amino acids

We describe here an efficient way to synthesize series of new urea- and thiocarbamate-tethered glycosyl β-amino acids under mild conditions. These glycosyl β-amino acids are elaborately designed on the basis of natural N-linked glycosides. They have the same side chain length as natural N-glycosyl amino acid while the main chain is replaced with β-amino acid chain. The linkage is an isostere of natural N-linked bond but exhibits competitive stability to chemical and enzymatic hydrolysis. This facile route is benefit from the choice of the commercially available l-aspartic acid as starting material, which not only provides a β-amino acid moiety, but also the α-carboxy group could be transformed to active isocyanate conveniently and economically. The prospective glycosyl β-amino acids are obtained readily by the reaction of isocyanate with appropriately protected glycosylamines and glycosylthiols.

Process for preparing deuterated desmosine and derivatives thereof

There is provided a process for preparing a compound represented by the following general formula (1) or a salt thereof, which comprises exchanging one or more of an amino proton in a compound represented by the following general formula (2) or a salt thereof to deuterium, and after the exchanging, converting a deuterium-exchanged compound of the compound represented by the general formula (2) or a salt thereof into the compound represented by the general formula (1) or a salt thereof: wherein, in the general formula (1), one, or two or more of hydrogen atom may be substituted with their isotope; and in the general formula (2), each of R1 is independently hydrogen atom, tert-butyloxycarbonyl group or benzyloxycarbonyl group, and R2 is independently tert-butyl group, benzyl group, methyl group or ethyl group.

Enantioselective Synthesis of a Tricyclic, sp3-Rich Diazatetradecanedione: an Amino Acid-Based Natural Product-Like Scaffold

6-, 7-, and 8-membered rings are assembled from a linear precursor by successive cyclisation reactions to construct a tricyclic diazatricyclo[6.5.1.04, 9]-tetradecanedione scaffold. Advanced building blocks based on d-aspartic acid and l-pyroglutamic acid were combined by a sp3?sp2 Negishi coupling. A carbamate-guided syn-diastereoselective epoxidation followed by an intramolecular epoxide opening allowed the construction of the piperidine ring. An efficient one-pot hydroxyl-group protection twofold deprotection reaction prepared the ground for the cyclisation to the bicycle. A final deprotection of the orthogonal protecting groups and lactamisation led to the novel, sp3-rich tricycle. The final compound is a substrate mimic of peptidyl-prolyl cis-trans isomerases featuring a locked trans-amide bond. Cheminformatic analysis of 179 virtual derivatives indicates favourable physicochemical properties and drug-like characteristics. As proof of concept we, show a low micromolar activity in a fluorescence polarisation assay towards the FK506-binding protein 12.

Multigram-scale and column chromatography-free synthesis of L-azetidine-2-carboxylic acid for the synthesis of nicotianamine and its derivatives

Multigram-scale synthesis of L-azetidine-2-carboxylic acid from L-aspartic acid was achieved in 13 conventional synthetic steps, without the need for purification by silica-gel column chromatography and expensive reagents. Nicotianamine and its fluorescence-labeled derivatives could be obtained from this synthetic strategy.

HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS

The present invention relates to compound of formula (I) (I) wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, espec

A 10th factor inhibitor and its preparation method and application (by machine translation)

The invention relates to a 10th factor inhibitor and its preparation and application, the 10th factor inhibitor has the structure of formula I, the invention inhibitors to alpha-amino acid as a template, respectively through the amide, carbamate, or urea to the branched chain is formed by a series of novel structure of the compound, this kind of compound can be effectively with the 10th factor binding, prevent the formation of thrombus. (by machine translation)

BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS

β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.